What is Dulaglutide?

A once-weekly GLP-1 receptor agonist (two GLP-1 analog chains joined to an antibody Fc fragment), sold as Trulicity.

Open the Dulaglutide reconstitution calculator

Dulaglutide in the library · Metabolic & Weight Peptides · Human Trials · What are peptides?

121 registered trials · 177 indexed papers · 490 human / 8 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

A once-weekly GLP-1 receptor agonist (two GLP-1 analog chains joined to an antibody Fc fragment), sold as Trulicity.

Type: GLP-1 receptor agonist peptide.

Human research

The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Dulaglutide is one of its interventions, or is named in the study title or subject headings.

Listing a study does not mean it showed a benefit, and it is not medical advice.

Registered human trials (121)

TrialPhaseStatusYearEnrolled
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesPhase 3recruiting2026170
Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.completed2026300000
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)completed202660000
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Riskcompleted2026120000
Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes MellitusPhase 2not yet recruiting202660
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney DiseasePhase 4not yet recruiting2026468
Weekly GLP-1 Receptor Agonists in Obese Individuals Without DiabetesPhase 3completed2025150
Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical TrialPhase 3completed2025159
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.Phase 4completed202592
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes MellitusPhase 1completed202520
A Study of Dulaglutide (LY2189265) [amount hidden] in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)Phase 3recruiting202555
Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes MellitusPhase 1/Phase 2enrolling by invitation202550
Role of GLP1 RA Dulaglutide on Severe Intracranial AtherosclerosisPhase 2/Phase 3recruiting2025130
A Phase 3 Study of HS-20094 in Patients With T2DMPhase 3not yet recruiting2025546
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or MetforminPhase 2recruiting2025216
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetescompleted202470000
GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac SurgeryPhase 4recruiting2024372
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes MellitusPhase 3completed2024632
Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent ThalassemiaPhase 2completed202480
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor AgonistsPhase 4active not recruiting202460
Holding vs. Continuing Incretin-based Therapies Before Upper EndoscopyPhase 4completed202469
Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Datacompleted202444671
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Riskcompleted2024887132
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminPhase 3active not recruiting2024600
A Study of HS-20094 in Patients With T2DMPhase 2completed2024275
Therapeutic Strategies for Microvascular Dysfunction in Type 1 DiabetesPhase 2recruiting202347
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKDrecruiting2023250
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DMPhase 3completed2023623
Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes MellitusPhase 2completed2023234
A Study of IBI362 in Participants With Type 2 DiabetesPhase 3completed2023731
The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesityunknown202360
Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2DPhase 4unknown2023135
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)Phase 4completed2022282
Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney DiseasePhase 2completed20227
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in IndiaPhase 4completed2022212
Basal Plus GLP1-ra on Glycemic Variability in CKDPhase 4completed202295
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes MellitusPhase 1completed202264
A Study of LY3532226 in Participants With Type 2 Diabetes MellitusPhase 1completed202290
A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 DiabetesPhase 1completed202294
A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese SubjectsPhase 1completed202268

Peer-reviewed studies (177)

PaperAuthorsJournalYearType
Dulaglutide vs insulin in adolescents with thalassaemia-induced diabetes: effect on metabolism and atherogenesis (DIADEMA)Adly AAM et al.Diabetologia2026Randomized Controlled Trial
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 DiabetesRuotolo G et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analysesJun JE et al.Frontiers in endocrinology2026Randomized Controlled Trial
Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 DiabetesNeumiller JJ et al.American journal of kidney diseases : the official journal of the National Kidney Foundation2026Observational Study
Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled TrialHeise T et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trialZoungas S et al.The lancet. Diabetes & endocrinology2026Randomized Controlled Trial
Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysisWilson JM et al.Alzheimer's & dementia : the journal of the Alzheimer's Association2026Randomized Controlled Trial
Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWINDSattar N et al.Diabetes care2026Randomized Controlled Trial
Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCHViolante-Ortiz R et al.BMJ open diabetes research & care2026Randomized Controlled Trial
Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical TrialNissen SE et al.JAMA cardiology2026Randomized Controlled Trial
[SURPASS CVOT : cardiovascular benefits with tirzepatide versus dulaglutide in type 2 diabetes]Scheen A et al.Revue medicale de Liege2026Clinical Study
Vascular and Myocardial Function in Patients with Type 2 Diabetes and Ischemic Stroke Treated with Dulaglutide or EmpagliflozinPavlidis G et al.Medicina (Kaunas, Lithuania)2026Observational Study
Effects of GLP-1 receptor agonists on copeptin in euvolemic participantsLeibnitz S et al.European journal of endocrinology2026Randomized Controlled Trial
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetesGuo L et al.Nature2026Randomized Controlled Trial
Glycemic Improvement with Low-Dose Dulaglutide Is Associated with Leptin and Obestatin Modulation in Type 2 Diabetes MellitusJung I et al.Diabetes & metabolism journal2026Observational Study
GLP-1 agonist-associated presentations to unscheduled care: An opportunistic pilot studyThomas O et al.British journal of clinical pharmacology2026Observational Study
Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and ExenatideBarkmeier AJ et al.Ophthalmology. Retina2026Observational Study
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesNicholls SJ et al.The New England journal of medicine2025Clinical Trial, Phase III
Effect of ketogenic diet plus dulaglutide on glucose and lipid metabolism in diabetes mellitusGao R et al.Pakistan journal of pharmaceutical sciences2025Randomized Controlled Trial
Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective studySeijas-Amigo J et al.Diabetes & metabolic syndrome2025Observational Study
Predictive factors of body weight loss in patients with type 2 diabetes treated with GLP-1 receptor agonists: a 52-week prospective real-life studyVozza A et al.Frontiers in endocrinology2025Observational Study
Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 studyKanu C et al.Diabetes, obesity & metabolism2025Randomized Controlled Trial
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trialHe Y et al.The lancet. Diabetes & endocrinology2025Randomized Controlled Trial
Trends in glucagon-like peptide 1 receptor agonist prescribing patternsUkhanova M et al.The American journal of managed care2025Observational Study
Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetesRosenstock J et al.Diabetes, obesity & metabolism2025Randomized Controlled Trial
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trialCoskun T et al.The lancet. Diabetes & endocrinology2025Randomized Controlled Trial
Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetesKishimori T et al.Scientific reports2025Observational Study
Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation StudiesSaeed A et al.Annals of internal medicine2025Observational Study
Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 CountriesLakhani M et al.American journal of ophthalmology2025Observational Study
Comparative evaluation of dulaglutide alone vs. dulaglutide combined with probiotics on cardiovascular risk factors in T2DMTian J et al.Hormones (Athens, Greece)2025Randomized Controlled Trial

More cited research

Conditions researched

Related compounds

FAQ

What is Dulaglutide?

A once-weekly GLP-1 receptor agonist (two GLP-1 analog chains joined to an antibody Fc fragment), sold as Trulicity.

How many registered human trials study Dulaglutide?

The PeptideWhiz trial index lists 121 registered trials for Dulaglutide, the most recent from 2026.

How much published research exists on Dulaglutide?

The PeptideWhiz paper index links 177 PubMed papers to Dulaglutide; by study type, 490 human and 8 animal studies.

Which conditions is Dulaglutide researched for?

Atherosclerosis, cardiovascular disease & high blood pressure, Chronic and systemic inflammation, Cognition, focus & brain performance, Concussion, traumatic brain injury & stroke recovery, Delayed gastric emptying on GLP-1 medicines, Dementia, Alzheimer's & cognitive decline, Diabetic retinopathy and glaucoma, Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes, Heart repair: after heart attack, heart failure & enlarged heart, Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), Lung health, asthma & COPD, PCOS.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research